Signal inhibition of TGFβ1 is often used for stem cell reprogramming and iPSC differentiation. Small kinase inhibitors are commonly used, but they lack specificity and may perturb other signaling pathways, causing cytotoxicity.
PG-002, a chemically-synthesized cyclic peptide with specific binding ability against TGFβ1 and lacks membrane-permeability, can specifically inhibit TGFβ1 signaling at extracellular conditions, making it a suitable replacement for small kinase inhibitors.
In an SBE reporter assay, PG-002 showed 100% TGFβ1 inhibitory activity at 10 nM against 0.13 nM TGFβ1, which is equivalent to the commercially available neutralizing antibody.
Provided as lyophilized powder
Purity: Greater than or equal to 95% (HPLC)
MW (Da): 2,587.90 (acetate)
https://peptigrowth.com/en/products/pg-002/
This content is hosted by a third party (youtube.com). To view external content you must agree to cookies.